Instituto Rosenbusch (BUE:ROSE) NonCurrent Deferred Liabilities: ARS0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BUE:ROSE Instituto Rosenbusch SA BUE:ROSE
37 GF Score
Price ARS159.50
GF Value ARS62.43
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Instituto Rosenbusch NonCurrent Deferred Liabilities?

Instituto Rosenbusch BUE:ROSE +3.57% 37 NonCurrent Deferred Liabilities is ARS0 Mil as of Dec. 2025. GuruFocus rates BUE:ROSE with a GF Score™ of 37/100 and a GF Value™ of ARS62.43 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Instituto Rosenbusch's non-current deferred liabilities for the quarter that ended in Dec. 2025 was ARS0 Mil.

Instituto Rosenbusch NonCurrent Deferred Liabilities Related Terms

Instituto Rosenbusch NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Instituto Rosenbusch's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Instituto Rosenbusch NonCurrent Deferred Liabilities Chart

Instituto Rosenbusch Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Instituto Rosenbusch Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BUE:ROSE
37GF Score
Instituto Rosenbusch SA BUE:ROSE
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of ARS0 Mil mean?
Instituto Rosenbusch (BUE:ROSE) has a NonCurrent Deferred Liabilities of ARS0 Mil as of Dec. 2025. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Instituto Rosenbusch and its competitors.
Is Instituto Rosenbusch's NonCurrent Deferred Liabilities too high?
Instituto Rosenbusch's current NonCurrent Deferred Liabilities is ARS0 Mil. Overall, Instituto Rosenbusch has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Instituto Rosenbusch's NonCurrent Deferred Liabilities compare to ZTS and UTHR?
Instituto Rosenbusch's NonCurrent Deferred Liabilities of ARS0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Drug Manufacturers company?
A good NonCurrent Deferred Liabilities depends on the Drug Manufacturers industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Instituto Rosenbusch and its competitors. Instituto Rosenbusch's current NonCurrent Deferred Liabilities is ARS0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Instituto Rosenbusch stock overvalued right now?
Based on GuruFocus' analysis, Instituto Rosenbusch (BUE:ROSE) is currently considered Significantly Overvalued. The stock's GF Value™ is ARS62.43, compared to a current price of ARS159.50 — trading 155.5% above its estimated fair value. The current NonCurrent Deferred Liabilities is ARS0 Mil. Instituto Rosenbusch's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Instituto Rosenbusch (BUE:ROSE), the current NonCurrent Deferred Liabilities is ARS0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Instituto Rosenbusch (BUE:ROSE) Overvalued in 2026?

Based on GuruFocus' analysis, Instituto Rosenbusch stock appears to be overvalued. The current stock price of ARS159.50 is trading 155.5% above its estimated GF Value™ of ARS62.43. GuruFocus considers Instituto Rosenbusch to be Significantly Overvalued.

Key valuation signals for BUE:ROSE:

  • NonCurrent Deferred Liabilities: ARS0 Mil
  • GF Value™: ARS62.43 vs. price of ARS159.50 (155.5% above fair value)
  • GF Score™: 37/100 with 4 warning signs

No single metric tells the full story. See the BUE:ROSE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Instituto Rosenbusch Business Description

Address Hipolito Yrigoyen 1628, Buenos Aires, ARG, C1089AAF
Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.
37GF Score

Get the complete analysis for BUE:ROSE

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS159.50
Price
ARS62.43
GF Value